FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 6, 2011, Pages 1029-1036

  Rousseau, Caroline ^a,b,f   Devillers, Anne ^c   Campone, Mario ^d   Campion, Loïc ^d   Ferrer, Ludovic ^d   Sagan, Christine ^e   Ricaud, Myriam ^d   Bridji, Boumédiène ^a   Kraeber Bodéré, Françoise ^a,b  

^a IRCNA   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d ICO Institut de Cancérologie de l Ouest   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

18F FDG PET; Breast carcinoma; Lymph node; Neoadjuvant chemotherapy; Response monitoring

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC ACCURACY; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 79958054236     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1735-y     Document Type: Article

References (44)

1. EP Mamounas 1998 Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies Semin Oncol 25 31 35 9566205 1:STN:280:DyaK1c3islehtQ%3D%3D (Pubitemid 28188642)
2. JY Pierga E Mouret V Diéras V Laurence P Beuzeboc T Dorval, et al. 2000 Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer Br J Cancer 83 1480 1487 11076657 10.1054/bjoc.2000.1461 1:STN:280:DC%2BD3M%2FmsFKisA%3D%3D
3. R Rouzier JM Extra J Klijanienko MC Falcou B Asselain A Vincent-Salomon, et al. 2002 Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes J Clin Oncol 20 1304 1310 11870173 10.1200/JCO.20.5.1304 (Pubitemid 34177437)
4. R Prati CA Minami JA Gornbein N Debruhl D Chung HR Chang 2009 Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy Cancer 115 1194 1202 19156919 10.1002/cncr.24154 1:CAS:528:DC%2BD1MXktlKns7c%3D
5. RL Wahl K Zasadny M Helvie GD Hutchins B Weber R Cody 1993 Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 2101 2111 8229124 1:STN:280:DyaK2c%2FksFyisQ%3D%3D (Pubitemid 23332245)
6. C Rousseau A Devillers C Sagan L Ferrer B Bridji L Campion, et al. 2006 Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography J Clin Oncol 24 5366 5372 17088570 10.1200/JCO.2006.05.7406 (Pubitemid 46623167)
7. P Bassa EE Kim T Inoue FC Wong M Korkmaz DJ Yang, et al. 1996 Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer J Nucl Med 37 931 938 8683314 1:CAS:528:DyaK28Xkt1KlsL4%3D (Pubitemid 126447124)
8. DA Mankoff LK Dunnwald JR Gralow GK Ellis EK Schubert J Tseng, et al. 2003 Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy J Nucl Med 44 1806 1814 14602864 (Pubitemid 39663314)
9. IC Smith AE Welch AW Hutcheon ID Miller S Payne F Chilcott, et al. 2000 Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 1676 1688 10764428 1:STN:280:DC%2BD3c3islyjsg%3D%3D (Pubitemid 30220546)
10. ME Straver TS Aukema RA Valdes Olmos EJ Rutgers KG Gilhuijs ME Schot, et al. 2010 Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients Eur J Nucl Med Mol Imaging 37 1069 1076 20130860 10.1007/s00259-009-1343-2
11. Sobin LH, Wittekind Ch. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
12. OG Rousset Y Ma AC Evans 1998 Correction for partial volume effects in PET: principles and validation J Nucl Med 39 904 911 9591599 1:STN:280:DyaK1c3lt1aksQ%3D%3D (Pubitemid 28216748)
13. Ferrer L, Grealou Y, Autret D, et al. A new ImageJ plugin to correct for partial effect volume. Eur J Nucl Med Mol Imaging 2004;31:Suppl 2 (abstract 120).
14. M Soret PM Koulibaly J Darcourt I Buvat 2006 Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification Eur J Nucl Med Mol Imaging 33 1062 1072 16639610 10.1007/s00259-005-0003-4 (Pubitemid 44215672)
15. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
16. DM Sataloff BA Mason AJ Prestipino UL Seinige CP Lieber Z Baloch 1995 Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J Am Coll Surg 180 297 306 7874340 1:STN:280:DyaK2M7nvFemsQ%3D%3D
17. M Kaufmann GN Hortobagyi A Goldhirsch S Scholl A Makris P Valagussa, et al. 2006 Recommendations from an international expert panel of the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940 1949 16622270 10.1200/JCO.2005.02.6187 (Pubitemid 46638994)
18. HM Kuerer LA Newman AU Buzdar K Dhingra KK Hunt TA Buchholz, et al. 1998 Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status Cancer J Sci Am 4 230 236 9689981 1:STN:280:DyaK1czlsVCgtw%3D%3D
19. C Gajdos PI Tartter A Estabrook MA Gistrak S Jaffer IJ Bleiweiss 2002 Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer J Surg Oncol 80 4 11 11967899 10.1002/jso.10090 (Pubitemid 34477727)
20. BT Hennessy AM Gonzalez-Angulo GN Hortobagyi M Cristofanilli SW Kau K Broglio B Fornage SE Singletary A Sahin AU Buzdar V Valero 2006 Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy Cancer 106 1000 1006 16444747 10.1002/cncr.21726
21. Uematsu T, Kasami M, Watanabe J, Takahashi K, Yamasaki S, Tanaka K, et al. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer? Breast Cancer 2010 Jun 24 [Epub ahead of print].
22. D Li Q Yao L Li J Chen 2007 Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer Cancer Biol Ther 6 1442 1448 17827982 10.4161/cbt.6.9.4621 1:CAS:528:DC%2BD1cXhtlCitLY%3D (Pubitemid 351590356)
23. DM Bruce NT Evans SD Heys G Needham H BenYounes P Mikecz, et al. 1995 Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers Eur J Surg Oncol 21 280 283 7781797 10.1016/S0748-7983(95)91492-7 1:STN:280:DyaK2MzgtV2qsQ%3D%3D
24. T Jansson JE Westlin H Ahlström A Lilja B Långström J Bergh 1995 Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13 1470 1477 7751894 1:STN:280:DyaK2M3ntFaksA%3D%3D
25. M Schelling N Avril J Nährig W Kuhn W Römer D Sattler, et al. 2000 Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689 1695 10764429 1:STN:280:DC%2BD3c3islyjsw%3D%3D (Pubitemid 30220547)
26. DA Mankoff LK Dunnwald JR Gralow GK Ellis TJ Lawton EK Schubert, et al. 2002 Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy J Nucl Med 43 500 509 11937594 (Pubitemid 34286345)
27. SJ Kim SK Kim ES Lee J Ro S Kang 2004 Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy Ann Oncol 15 1352 1357 15319241 10.1093/annonc/mdh345 (Pubitemid 39295023)
28. J Dose Schwarz M Bader L Jenicke G Hemminger F Jänicke N Avril 2005 Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med 46 1144 1150 16000283 (Pubitemid 43741076)
29. GM McDermott A Welch RT Staff FJ Gilbert L Schweiger SI Semple, et al. 2007 Monitoring primary cancer throughout chemotherapy using FDG-PET Breast Cancer Res Treat 102 75 84 16897427 10.1007/s10549-006-9316-7 1:CAS:528:DC%2BD2sXhslCltrg%3D (Pubitemid 46294965)
30. A Berriolo-Riedinger C Touzery JM Riedinger M Toubeau B Coudert L Arnould, et al. 2007 [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy Eur J Nucl Med Mol Imaging 34 1915 1924 17579854 10.1007/s00259-007-0459-5 1:CAS:528:DC%2BD2sXhtlyiurzL (Pubitemid 350212117)
31. M Tozaki M Sakamoto Y Oyama T O'uchi N Kawano T Suzuki, et al. 2008 Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography J Magn Reson Imaging 28 420 427 18666159 10.1002/jmri.21454
32. J Duch D Fuster M Muñoz PL Fernández P Paredes M Fontanillas, et al. 2009 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer Eur J Nucl Med Mol Imaging 36 1551 1557 19326117 10.1007/s00259-009-1116-y 1:CAS:528:DC%2BD1MXht1WhtL3L
33. A Kumar R Kumar V Seenu SD Gupta M Chawla A Malhotra, et al. 2009 The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur Radiol 19 1347 1357 19214522 10.1007/s00330-009-1303-z
34. A Thomas R Ohlinger M Hauschild A Mustea JU Blohmer S Kümmel 2006 Options and limits of surgery after pre-operative chemotherapy in breast cancer Anticancer Res 26 1677 1682 16617561 1:CAS:528:DC%2BD28XktVGqsL8%3D
35. K Dalus G Rendl L Rettenbacher C Pirich 2010 FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients Eur J Nucl Med Mol Imaging 37 1992 1993 20700738 10.1007/s00259-010-1585-z
36. P Chollet S Amat H Cure M de Latour G Le Bouedec MA Mouret-Reynier, et al. 2002 Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer Br J Cancer 86 1041 1046 11953845 10.1038/sj.bjc.6600210 1:STN:280:DC%2BD383hs1KgsA%3D%3D (Pubitemid 34441058)
37. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 10080586 1:CAS:528:DyaK1MXht1Wmur4%3D (Pubitemid 29075229)
38. NC Krak OS Hoekstra AA Lammertsma 2004 Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations Eur J Nucl Med Mol Imaging 31 S103 S111 15103507 10.1007/s00259-004-1532-y
39. J Herrada RB Iyer EN Atkinson N Sneige AU Buzdar GN Hortobagyi 1997 Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma Clin Cancer Res 3 1565 1569 9815844 1:STN:280:DyaK1M7htFSqsQ%3D%3D (Pubitemid 27431564)
40. L Ollivier C Balu-Maestro J Leclère 2005 Imaging in evaluation of response to neoadjuvant breast cancer treatment Cancer Imaging 5 27 31 16154816 10.1102/1470-7330.2005.0009 1:STN:280:DC%2BD2MvotlWqtA%3D%3D
41. L Martincich F Montemurro G De Rosa V Marra R Ponzone S Cirillo, et al. 2004 Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging Breast Cancer Res Treat 83 67 76 14997056 10.1023/B:BREA.0000010700.11092.f4 (Pubitemid 38141894)
42. D Segara IE Krop JE Garber E Winer L Harris JR Bellon, et al. 2007 Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96 474 480 17640031 10.1002/jso.20856 (Pubitemid 350044390)
43. S Javid D Segara P Lotfi S Raza M Golshan 2010 Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy Ann Surg Oncol 17 1841 1846 20143266 10.1245/s10434-010-0934-2
44. T Harada N Tanigawa M Matsuki T Nohara I Narabayashi 2007 Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging Eur J Radiol 63 401 407 17398053 10.1016/j.ejrad.2007.02.010 (Pubitemid 47321038)